Dr Shannon Westin (MD Anderson Cancer Center, Houston, USA), Dr Brian Slomovitz (Mount Sinai Medical Center, Miami, USA), Dr Vanda Salutari (Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy) and Dr Christian Marth (Innsbruck Medical University, Innsbruck, Austria) discuss the most impactful data in endometrial cancer presented at ESMO 2025.

The panel discusses latest survival, biomarker, and quality-of-life outcomes from pivotal phase III trials in endometrial cancer.

They highlight the impact of immunotherapy and targeted agents, including combinations such as atezolizumab, pembrolizumab, lenvatinib, and durvalumab.

Clinical relevance of genomic tools such as WES-derived aneuploidy scores (W-AS) for patient stratification and prediction of treatment response are also covered.

They conclude by talking about where new therapies fit among established standards and what this means for routine clinical practice.